Profound Medical Corp.
PROFNASDAQHealthcare● Active
$6.55
$-0.11(-1.65%)
Market Cap$198199057
P/E Ratio—
52W High$8.95
52W Low$3.76
Profound Medical Corp. (PROF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PROF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.19
Est. -$0.24 · +20.8%
Revenue
$0.01B
Est. $0.00B · +10.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
PROF reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.22 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.24 | -$0.19 | +20.8% | $0.01B | $0.00B | +10.0% |
| — Q1 FY2026 | Mar 5, 2026 | -$0.27 | -$0.27 | +0.0% | $0.01B | $0.01B | -22.0% |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.38 | -$0.26 | +31.6% | $0.01B | $0.01B | -50.3% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.43 | -$0.52 | -20.9% | $0.00B | $0.00B | -53.3% |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.29 | -$0.36 | -24.1% | $0.00B | $0.00B | -44.1% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.31 | -$0.20 | +35.5% | $0.01B | $0.01B | -10.0% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.30 | -$0.38 | -26.7% | $0.00B | $0.01B | -35.4% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.22
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.24
EPS Surpr.
+20.8%
Revenue
$0.01B
Q1 FY2026
Mar 5, 2026
EPS Actual
-$0.27
EPS Est.
-$0.27
EPS Surpr.
+0.0%
Revenue
$0.01B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.26
EPS Est.
-$0.38
EPS Surpr.
+31.6%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.52
EPS Est.
-$0.43
EPS Surpr.
-20.9%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.36
EPS Est.
-$0.29
EPS Surpr.
-24.1%
Revenue
$0.00B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.31
EPS Surpr.
+35.5%
Revenue
$0.01B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.38
EPS Est.
-$0.30
EPS Surpr.
-26.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.08 | $0.10 | $0.12 | 1 |
| Q3 FY2028 | $0.07 | $0.08 | $0.09 | 1 |
| Q2 FY2028 | $0.03 | $0.04 | $0.05 | 1 |
| Q1 FY2028 | $0.02 | $0.02 | $0.02 | 1 |
| Q4 FY2027 | $-0.10 | $-0.08 | $-0.07 | 1 |
| Q3 FY2027 | $-0.15 | $-0.13 | $-0.11 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +20.8% | $7.22 | $7.16 | -0.83% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +0.0% | $7.48 | $7.49 | +0.13% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +31.6% | $6.47 | $6.35 | -1.85% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -20.9% | $5.45 | $5.54 | +1.65% |
| ▼ Q2 FY2025 | May 8, 2025 | -24.1% | $4.81 | $4.98 | +3.53% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +35.5% | $7.33 | $7.29 | -0.55% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -26.7% | $8.00 | $8.96 | +12.00% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +3.5% | $9.60 | $9.62 | +0.21% |
Q2 FY2026-0.83%
Report Date
May 7, 2026
EPS Beat/Miss
+20.8%
Price Before
$7.22
Price After
$7.16
Q1 FY2026+0.13%
Report Date
Mar 5, 2026
EPS Beat/Miss
+0.0%
Price Before
$7.48
Price After
$7.49
Q4 FY2025-1.85%
Report Date
Nov 13, 2025
EPS Beat/Miss
+31.6%
Price Before
$6.47
Price After
$6.35
Q3 FY2025+1.65%
Report Date
Aug 14, 2025
EPS Beat/Miss
-20.9%
Price Before
$5.45
Price After
$5.54
Q2 FY2025+3.53%
Report Date
May 8, 2025
EPS Beat/Miss
-24.1%
Price Before
$4.81
Price After
$4.98
Q1 FY2025-0.55%
Report Date
Mar 6, 2025
EPS Beat/Miss
+35.5%
Price Before
$7.33
Price After
$7.29
Q4 FY2024+12.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
-26.7%
Price Before
$8.00
Price After
$8.96
Q3 FY2024+0.21%
Report Date
Aug 8, 2024
EPS Beat/Miss
+3.5%
Price Before
$9.60
Price After
$9.62
Avg Beat Reaction-0.58%
Avg Miss Reaction+5.73%
Beat Rate5 / 8 quarters
Largest Move+12.00% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PROF ends December
Profound Medical Corp. (PROF) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.24 by +20.8%. PROF has beaten EPS estimates for 3 consecutive quarters. The next PROF earnings date is expected around September 1, 2026.
Each quarter, investors track PROF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PROF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PROF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PROF earnings · 5 questionsProfound Medical Corp.'s next earnings report is expected around September 1, 2026. PROF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PROF historically reports after market close (AMC).
PROF earnings datewhen is PROF earningsPROF next earnings datewhen does PROF report earningsPROF earnings calendar
▸ Source: FMP · Profound Medical Corp. SEC filings · US GAAP · Profound Medical Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026